Overcoming Antimicrobial Resistance

Episode Summary

Executive Summary: The episode examines drug-resistant gonorrhea as a growing public health threat and profiles Taxis Pharmaceuticals’ strategy to develop first-in-class antimicrobials that avoid existing resistance patterns. CEO Greg Mario describes lead candidate TXA15054, an NIH-funded DHFR inhibitor with strong animal-model efficacy and narrow-spectrum activity, alongside a broader anti-resistance platform using efflux pump inhibitors to revive older antibiotics. The conversation also covers antibiotic market failures, public funding, and the need for new incentives like the Pasteur Act.

Main Topics: Drug-resistant gonorrhea as a public health emergency (Priority: 5/5): The discussion frames gonorrhea as a common sexually transmitted infection that is increasingly resistant to available antibiotics, creating a risk that infections may become untreatable without new therapies. TXA15054 as a first-in-class gonorrhea candidate (Priority: 5/5): Taxis’ lead program targets dihydrofolate reductase (DHFR) in a novel way for gonorrhea, aiming for high potency, narrow spectrum activity, and less disruption of the gut microbiome. Broader anti-resistance platform and efflux pump inhibitors (Priority: 4/5): Beyond gonorrhea, Taxis is developing technologies that disrupt bacterial cell-wall-related resistance mechanisms, including efflux pump inhibitors that can restore older antibiotics. Preclinical evidence and development path (Priority: 4/5): Mario outlines animal-model data showing rapid clearance of resistant gonorrhea strains, and describes the next steps: lead optimization, toxicity balancing, and eventual phase 1 trials. Economics of antibiotics and the need for incentives (Priority: 5/5): The episode argues that antibiotic development failed largely because of poor economics, not just scientific risk, and that public/private incentives are needed to bring companies back into the space. Funding strategy and partnership model (Priority: 3/5): Taxis has relied on private capital plus non-dilutive grants and expects partnerships or milestone-based deals to fund later-stage development; an IPO is mentioned as a potential route if the company advances further on its own.

Key Arguments: Drug-resistant gonorrhea is worsening and existing therapies, including ceftriaxone, are losing effectiveness. A third of new gonorrhea cases may already be drug-resistant, indicating a major treatment gap. TXA15054 is differentiated because it is narrow-spectrum and designed to avoid harming beneficial gut bacteria. Resistance to any antibiotic is inevitable over time, so the goal is to extend utility by using novel mechanisms and developing a pipeline of new agents. Taxis’ efflux pump inhibitor platform can resurrect older antibiotics by preventing bacteria from expelling them. Antibiotic market failure is driven by weak returns on short-course, curative drugs, not merely by resistance concerns. Public incentives such as NIH grants and the proposed Pasteur Act are essential to de-risk development and attract private capital. Partnerships with larger pharma companies are viewed as the likely path for late-stage development and commercialization.

Data Points: Projected annual AMR deaths by 2050: up to 10 million - Cited as the broader antimicrobial resistance threat framing the discussion WHO estimate of new gonorrhea infections in 2020: 82 million - Global burden of gonorrhea cited by Greg Mario CDC estimate of annual gonorrhea infections: over 1.6 million - U.S. annual infection estimate mentioned in the interview Estimated share of new gonorrhea cases that are drug-resistant: about one third - Mario’s estimate of resistant infections Estimated annual resistant gonorrhea cases: about half a million per year - Derived from the one-third estimate NIH grant for lead gonorrhea program: $2.97 million - Support for TXA15054 development NIH grant for efflux pump inhibitor platform: $2.67 million - Support for the EPI program Earlier CarbX/public-private grant: $3.2 million - First major grant Taxis received for antibiotic development Total private capital raised since inception: over $23 million - Raised from high-net-worth individuals and family offices Total non-dilutive funding: approximately $10 million - Combined grant support from NIH, CarbX, and related sources Preclinical efficacy timeline: undetectable in 3 days - Animal study result for TXA15054 against resistant gonorrhea strains Antibiotic classes revived by EPI platform: 28 old generic drugs from 10 classes - Mario claims the platform can restore activity to prior antibiotics

Pivotal Quotes: "We're running out rapidly. And certain strains are so highly resistant that even ceftriaxone, the gold standard drug for many years, doesn't work very well." — Greg Mario: Describing the urgency of drug-resistant gonorrhea and the shrinking therapeutic arsenal "Within three days, same animals... undetectable. In three days, no gonorrhea bacteria. It was all gone." — Greg Mario: Summarizing preclinical efficacy of TXA15054 in infected animal models "Instead, we're developing anti-resistance solutions. These are transformational innovations." — Greg Mario: Explaining Taxis’ strategy versus incremental next-generation antibiotics

Implications: If Taxis’ programs translate clinically, they could add durable new tools against resistant gonorrhea and broader AMR. More broadly, the episode argues that public funding and market incentives will determine whether antibiotic innovation rebounds.